Monitoring the efficacy and safety of three artemisinin based-combinations therapies in Senegal: results from two years surveillance
Background: Malaria remains a major public health problem in developing countries. Then in these countries
prompt access to effective antimalarial treatment such as Artemisinin based-Combination Therapies (ACT) proves to
be an essential tool for controlling the disease. In Senegal, since 2006 a nationwide scaling up program of ACT is
being implemented. In this context it has become relevant to monitor ACT efficacy and provide recommendations
for the Senegalese national malaria control program.
Methods: An open randomized trial was conducted during two malaria transmission seasons (2011 and 2012) to
assess the efficacy and safety of three combinations: dihydro-artemisinin-piperaquine (DHAPQ), artemetherlumefantrine
(AL) and artesunate-amodiaquine (ASAQ). The primary end point of the study was represented by a
PCR adjusted adequate clinical and parasitological response (ACPR) at day 28. Secondary end points included: (i) a
ACPR at days 35 and 42, (ii) a parasite and fever clearance time, (iii) ACTs safety and tolerability. The 2003 WHO’s
protocol for antimalarial drug evaluation was used to assess each outcome.
Results: Overall, 534 patients were randomized selected to receive, either ASAQ (n = 180), AL (n = 178) or DHAPQ
(n = 176). The PCR adjusted ACPR at day 28 was 99.41% for the group ASAQ, while that was 100% in the AL and
DHAPQ groups (p = 0.37). The therapeutic efficacy was evaluated at 99.37% in the ASAQ arm versus 100% in AL
and DHAPQ arm at day 35 (p = 0.37). At day 42, the ACPR was 99.27% in the ASAQ group versus 100% for both AL
and DHAPQ groups, (p = 0.36). No serious adverse event was noted during the study period. Also a similar safety
profile was noted in the 3 study groups.
Conclusion: In the context of scaling up of ACTs in Senegal, ASAQ, AL and DHAPQ are highly effective and safe
antimalarial drugs. However, it’s remains important to continue to monitor their efficacy.
Trial registration: PACTR 201305000552290.
Auteur(s) : Dr Khadime Sylla
Pages : 1471-2334
Année de publication : 2013
Revue : BMC Infectious Diseases
N° de volume : 13/598
Type : Article
Statut Editorial : Open Access
Mise en ligne par : SYLLA Khadime